Welcome to visit Zhongnan Medical Journal Press Series journal website!

Home Articles Vol 33,2024 No.1 Detail

Review and risk information management of neuropathy induced by emerging anti-tumor drugs

Published on Dec. 06, 2023Total Views: 1389 times Total Downloads: 529 times Download Mobile

Author: LYU Feng 1 SONG Wei 1 XIN Mengru 2 XIE Di 2 ZHANG Wenqing 2 HE Wen 1 HU Hankun 2, 3

Affiliation: 1. Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan 430060, China 2. Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 3. Professional Committee of General Practice, Beijing Neurology Association, Beijing 100012, China

Keywords: Emerging anti-tumor drugs Drug-induced neuropathy Drug risk information management

DOI: 10.12173/j.issn.1005-0698.202304130

Reference: LYU Feng, SONG Wei, XIN Mengru, XIE Di, ZHANG Wenqing, HE Wen, HU Hankun.Review and risk information management of neuropathy induced by emerging anti-tumor drugs[J].Yaowu Liuxingbingxue Zazhi,2024, 33(1):9-18.DOI: 10.12173/j.issn.1005-0698.202304130.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

As an increasing number of emerging anti-tumor drugs are approved and marketed, the imperative for clinical safety monitoring and risk information management has grown significantly. Drug-induced neuropathy associated with these drugs exhibit characteristics such as insidious onset, rapid progression, and challenging treatment, ultimately leading to treatment failures. Therefore, a comprehensive understanding of the risk of neuropathy induced by emerging anti-tumor drugs, coupled with risk surveillance and early warning, as well as management and reporting, can significantly reduce the incidence and severity of drug-related diseases. This paper provides a review of the neuropathy caused by emerging anti-tumor drugs, introduces the pharmacovigilance system and risk information management measures in clinical usage, aiming to provide a reference for guiding the rational clinical use and minimizing the incidence of drug-induced diseases.

Full-text
Please download the PDF version to read the full text: download
References

1.World Health Organization. WHO outlines steps to save 7 million lives from cancer [EB/OL]. (2020-02-04) [2023-04-28]. https://www.who.int/zh/news/item/04-02-2020-who-outlines-steps-to-save-7-million-lives-from-cancer.

2.Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9.0000000000002108.

3.国家卫健委办公厅. 国家卫生健康委办公厅关于印发新型抗肿瘤药物临床应用指导原则(2022年版)的通知 [EB/OL]. (2022-12-29) [2023-04-30]. http://www.nhc.gov.cn/yzygj/s7659/202212/8df034c9afb44a9d95cd986d4e12fbd8.shtml.

4.Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature[J]. Ann Oncol, 2017, 28(2): 377-385. DOI: 10.1093/annonc/mdw558.

5.Was H, Borkowska A, Bagues A, et al. Mechanisms of chemotherapy-induced neurotoxicity[J]. Front Pharmacol, 2022, 13: 750507. DOI: 10.3389/fphar.2022.750507.

6.Li JY, Ren YP, Yuan Y, et al. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice[J]. Acta Pharmacol Sin, 2016, 37(7): 930-940. DOI: 10.1038/aps.2016.55.

7.Bhullar KS, Lagarón NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions[J]. Mol Cancer, 2018, 17(1): 48. DOI: 10.1186/s12943-018-0804-2.

8.杨飒, 蒲兴祥, 王倩之, 等. 1例奥希替尼致神经毒性不良反应报道[J]. 肿瘤药学, 2022, 12(2): 272-276. [Yang S, Pu XX, Wang QZ, et al. A case report of osimertinib-induced neurotoxicity[J]. Anti-Tumor Pharmacy, 2022, 12(2): 272-276.] DOI: 10.3969/j.issn.2095-1264.2022.02.22.

9.俞燕华. 吉非替尼致神经性耳聋1例[J]. 医药导报, 2019, 38(8): 1098-1099. [Yu YH. Neurogenic deafness induced by gefitinib: a case report[J]. Herald of Medicine, 2019, 38(8): 1098-1099.] DOI: 10.3870/j.issn.1004-0781.2019.08.027.

10.López BM, Toro BC, Sais GE, et al. Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer[J]. Anticancer Drugs, 2018, 29(4): 380-383. DOI: 10.1097/CAD.0000000000000600.

11.Koshikawa H, Tsukie T, Kurita A, et al. Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy[J]. J Infect Chemother, 2017, 23(11): 798-799. DOI: 10.1016/j.jiac.2017.04.014.

12.Kanaan Z, Kulairi Z, Titianu M, et al. Guillain-Barré syndrome following treatment with sunitinib malate[J]. Case Rep Oncol Med, 2014, 2014: 712040. DOI: 10.1155/2014/712040.

13.Aparicio-Gallego G, Blanco M, Figueroa A, et al. New insights into molecular mechanisms of sunitinib-associated side effects[J]. Mol Cancer Ther, 2011, 10(12): 2215-2223. DOI: 10.1158/1535-7163.

14.Reed M, Rosales AS, Chioda MD, et al. Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners[J]. Adv Ther, 2020, 37(6): 3019-3030. DOI: 10.1007/s12325-020-01365-3.

15.Staropoli N, Ciliberto D, Del Giudice T, et al. The era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2018, 131: 83-89. DOI: 10.1016/j.critrevonc.2018.08.011.

16.Zhao H, Sifakis EG, Sumida N, et al. PARP1- and CTCF-mediated interactions between active and repressed chromatin at the lamina promote oscillating transcription[J]. Mol Cell, 2015, 59(6): 984-997. DOI: 10.1016/j.molcel.2015.07.019.

17.李玲, 林安, 林亮, 等. PARP抑制剂在卵巢癌维持治疗中非血液学不良反应的管理[J]. 现代妇产科进展, 2020, 29(10): 783-787. [Li L, Lin A, Lin L, et al. Management of nonhematological adverse effects of PARP inhibitors in ovarian cancer maintenance therapy[J]. Progress in Obstetrics and Gynecology, 2020, 29(10): 783-787.] DOI: 10.13283/j.cnki.xdfckjz.2020.10.012.

18.中国药师协会肿瘤专科药师分会, 中国抗癌协会肿瘤临床药学专业委员会, 浙江省抗癌协会肿瘤临床药学专业委员会, 等. 聚腺苷二磷酸核糖聚合酶抑制剂药物相互作用管理中国专家共识(2023版)[J]. 中华肿瘤杂志, 2023, 45(7): 584-593. DOI: 10.3760/cma.j.cn112152-20221223-00849.

19.Adams J, Kauffman M. Development of the proteasome inhihitor veleade (bortezomib)[J]. Cancer Invest, 2004, 22(2): 304-311. DOI: 10.1081/cnv-120030218.

20.任咏惠, 李丽, 汪梅, 等. 硼替佐米致多发性骨髓瘤患者周围神经病变的研究进展[J]. 临床医学研究与实践, 2022, 7(4): 196-198. [Ren YH, Li L, Wang M, et al. Research progress of bortezomib-induced peripheral neuropathy in patients with multiple myeloma[J]. Clinical Research and Practice, 2022, 7(4): 196-198.] DOI: 10.19347/j.cnki.2096-1413.202204056.

21.Sheng Z, Li G, Li B, et al. Carfilzomib-containing combinations as frontline therapy for multiple myeloma: a meta-analysis of 13 trials[J]. Eur J Haematol, 2017, 98(6): 601-607. DOI: 10.1111/ejh.12877.

22.郭志成, 吴涛, 白海. 伊沙佐米治疗多发性骨髓瘤研究进展[J]. 白血病·淋巴瘤, 2020, 29(8): 505-508. [Guo ZC, Wu T, Bai M. Research progress of isazzomib in the treatment of multiple myeloma[J]. Journal of Leukemia and Lymphoma, 2020, 29(8): 505-508.] DOI: 10.3760/cma.j.cn115356-20191014-00201.

23.Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: a current review[J]. Ann Neurol, 2017, 81(6): 772-781. DOI: 10.1002/ana.24951.

24.张文庆, 吴菁, 谢地, 等. 临床新兴抗肿瘤治疗方法发展概述[J]. 肿瘤防治研究, 2022, 49(3): 176-181. [Zhang WQ, Wu J, Xie D, et al. Review of development of emerging clinical antitumor therapeutics[J]. Cancer Research on Prevention and Treatment, 2022, 49(3): 176-181.] DOI: 10.3971/j.issn.1000-8578.2022.21.1034.

25.Michot JM, Lappara A, Le Pavec J, et al. The 2016-2019 immunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study[J]. Eur J Cancer, 2020, 130: 39-50. DOI: 10.1016/j.ejca.2020.02.010.

26.Albarrán V, Chamorro J, Rosero DI, et al. Neurologic toxicity of immune checkpoint inhibitors: a review of literature[J]. Front Pharmacol, 2022, 13: 774170. DOI: 10.3389/fphar.2022.774170.

27.吴汀溪, 张杨, 石延枫, 等. 基于美国FAERS数据库对免疫检查点抑制剂相关神经毒性的分析研究[J]. 中国药物应用与监测, 2023, 20(1): 50-54. [Wu TX, Zhang Y, Shi YF, et al. Analysis of neurological toxicities associated with immune checkpoint inhibitor based on the FDA adverse event reporting system[J]. Chinese Journal of Drag Application and Monitoring, 2023, 20(1): 50-54.] DOI: 10.3969/j.issn.1672-8157.2023.01.012.

28.Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study[J]. J Immunother Cancer, 2019, 7(1): 134. DOI: 10.1186/s40425-019-0617-x.

29.Moreira A, Loquai C, Pföhler C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors[J]. Eur J Cancer, 2019, 106: 12-23. DOI: 10.1016/j.ejca.2018.09.033.

30.Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors[J]. Expert Opin Drug Saf, 2020, 19(4): 479-488. DOI: 10.1080/14740338.2020.1738382.

31.Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update[J]. J Clin Oncol, 2021, 39(36): 4073-4126. DOI: 10.1200/JCO.21.01440.

32.田磊, 王志妍, 杨琼, 等. 使用利妥昔单抗后出现可逆性后部脑病综合征1例[J]. 临床药物治疗杂志, 2020, 18(10): 83-86. [Tian L, Wang ZY, Yang Q, et al. Posterior reversible encephalopathy syndrome after rituximab administration:a case report[J]. Clinical Medication Journal, 2020, 18(10): 83-86.] DOI: 10.3969/j.issn.1672-3384.2020.10.019.

33.曹义海. 血管生成在疾病治疗中的应用与展望[J]. 山东大学学报(医学版), 2021, 59(9): 9-14. [Cao YH. Targeting angiogenesisfor disease therapy[J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 9-14.] DOI: 10.6040/j.issn.1671-7554.0.2021.0936.

34.Matsuoka A, Maeda O, Mizutani T, et al. Bevacizumab exacerbates paclitaxel-induced neuropathy: a retrospective cohort study[J]. PLoS One, 2016, 11(12): e0168707. DOI: 10.1371/journal.pone.0168707.

35.Eaton JS, Miller PE, Mannis MJ, et al. Ocular adverse events associated with antibody - drug conjugates in human clinical trials[J]. J Ocul Pharmacol Ther, 2015, 31: 589-604. DOI: 10.1089/jop.2015.0064.

36.Sterenczak KA, Stache N, Bohn S, et al. Burst of corneal dendritic cells during trastuzumab and paclitaxel treatment[J]. Diagnostics (Basel), 2021, 11(5): 838. DOI: 10.3390/diagnostics11050838.

37.Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress[J]. Nat Rev Cancer, 2008, 8(6): 473-480. DOI: 10.1038/nrc2394.

38.Liu K, Li YH, Zhang X, et al. Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials[J]. Expert Rev Clin Pharmacol, 2022, 15(11): 1343-1350. DOI: 10.1080/17512433.2022.2121704.

39.宋红芳, 徐香, 朱霞明, 等. 16例贝林妥欧单抗治疗的急性淋巴细胞白血病患者临床护理报告[J]. 护理实践与研究, 2023, 20(5): 784-788. [Song HF, Xu X, Zhu MX, et al. Clinical care report of 16 patients with acute lymphoblastic leukemia treated with belintuzumab[J]. Nursing Practice and Research, 2023, 20(5): 784-788.] DOI: 10.3969/j.issn.1672-9676.2023.05.032.

40.Lühder F, Höglund P, Allison JP, et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes[J]. J Exp Med, 1998, 187(3): 427-432. DOI: 10.1084/jem.187.3.427.

41.Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials[J]. Cancer Immun, 2010, 10: 9. https://pubmed.ncbi.nlm.nih.gov/20957980/.

42.Inamura K. Roles of microbiota in response to cancer immunotherapy[J]. Semin Cancer Biol, 2020, 65: 164-175. DOI: 10.1016/j.semcancer.2019.12.026.

43.杨春松, 杨亚亚, 林芸竹, 等. 四川地区抗肿瘤药物风险分级现状及需求研究[J]. 儿科药学杂志, 2023, 29(2): 7-12. [Yang CS, Yang YY, Lin YZ, et al. Study on the status and demand of risk classification of antitumor drugs in Sichuan[J]. Journal of Pediatric Phaemacy, 2023, 29(2): 7-12.] DOI: 10.13407/j.cnki.jpp.1672-108X.2023.02.002.

44.邰宵辉,张玲芳,党春艳,等. 抗肿瘤药物致心脏损伤的药物防治进展[J]. 临床肿瘤学杂志, 2023, 28(1): 70-76. [Tai XH, Zhang LF, Dang CY, et al. Advances in the prevention and treatment of cardiotoxicity caused by anti-tumor drugs[J]. Chinese Clinical Oncology, 2023, 28(1): 70-76.] DOI: 10.3969/j.issn.1009-0460.2023.01.010.

45.彭楠茵,余国龙. 抗肿瘤药物心血管毒性及其相关风险评估研究进展[J]. 实用药物与临床, 2022, 25(8): 745-749. [Peng NY, Yu GL. Research progress on cardiovascular toxicity of anti-tumor drugs and related risk assessment[J]. Practical Pharmacy and Clinical Remedies, 2022, 25(8): 745-749.] DOI: 10.14053/j.cnki.ppcr.202208015.

46.傅晶. 风险管理在医院抗肿瘤药物安全管理中的应用[J]. 中医药管理杂志, 2021, 29(10): 204-205. [Fu J. Application of risk management in safety management of antitumor drugs in hospital[J]. Journal of Traditional Chinese Medicine Management, 2021, 29(10): 204-205.] https://d.wanfangdata.com.cn/periodical/zyyglzz202110089.

47.杨志敏. 药品说明书的规范性与风险控制——以新型抗肿瘤药为例[J]. 中国食品药品监管, 2019, (11): 40-47. [Yang ZM. Standardization and risk control of drug package inserts-- noval antitumor drugs, for example[J]. China Food & Drug Administration Magazine, 2019, (11): 40-47.] DOI: 10.3969/j.issn.1673-5390.2019.11.

48.洪英子, 胡骏. 新型抗肿瘤药的药物警戒体系概述[J]. 上海医药, 2022, 43(z2): 116-120. [Hong YZ, Hu Jun. Pharmacovigilance system in novel anti-tumor drugs[J]. Shanghai Medical & Pharmaceutical Journal, 2022, 43(z2): 116-120.] DOI: 10.3969/j.issn.1006-1533.2022.z2.015.

49.胡歆雅, 梁玉清, 曾亚莉, 等. 中美药物警戒制度的比较研究[J]. 中国合理用药探索, 2020, (2): 21-25. [Hu XY, Liang YQ, Zeng YL, et al. A comparative analysis of the pharmacovigilance system in China and the United States[J]. Chinese Journal of Rational Drug Use, 2020, (2): 21-25.] DOI: 10.3969/j.issn.2096-3327.2020.2.004.

50.Gutiérrez-Gutiérrez G, Sereno M, Miralles A, et al. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies[J]. Clin Transl Oncol, 2010, 12(2): 81-91. DOI: 10.1007/S12094-010-0474-z.

51.Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies[J]. Neth J Med, 2012, 70(1): 18-25. https://pubmed.ncbi.nlm.nih.gov/22271810/.

52.García-Sanz R, Corchete LA, Alcoceba M, et al. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array[J]. Hematol Oncol, 2017, 35(4): 746-751. DOI: 10.1002/hon.2337.

53.董超. 抗肿瘤药物所致神经毒性防治的研究进展[J]. 重庆医学, 2018, 47(2): 268-272. [Dong C. Research progress in prevention and treatment of neurotoxicity caused by antitumor drugs[J]. Chongqing Medicine, 2018, 47(2): 268-272.] DOI: 10.3969/j.issn.1671-8348.2018. 02.043.

54.Zajączkowska R, Kocot-Kępska M, Leppert W, et al. Mechanisms of chemotherapy-induced peripheral neuropathy[J]. Int J Mol Sci, 2019, 20(6): 1451. DOI: 10.3390/ijms20061451.

55.张晓雯, 侯文斌, 杨鸣, 等. 药物警戒研究在癌症治疗领域的机遇与挑战[J]. 中国药物警戒, 2021, 18(11): 1034-1038. [Zhang XW, He WB, Yang M, et al. Opportunities and Challenges of Pharmacovigilance in Cancer Treatment[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1034-1038.] DOI: 10.19803/j.1672-8629. 2021.11.08.

56.曹聚耕, 马明慧, 许丽扬, 等. 欧盟电子健康(eHealth)国家战略与我国卫生信息化刍议[C]. 中华医学会第十七次全国医学信息学术会议论文集, 2011: 1-3.

Popular papers
Last 6 months